Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health"), today released the Salix Liver Health Annual Trends Report, Second Edition with the latest information on chronic liver disease (CLD) care and findings that include a continued rise in hospitalizations and mortality from CLD and cirrhosis, as well as gaps in care and knowledge that may prevent early diagnosis and optimal management of CLD, cirrhosis and its complications.
The trends report, which is based on a survey of 400 health care providers (HCPs) who treat patients with CLD, qualitative interviews with HCPs, and secondary research from peer-reviewed publications, reveals shortfalls in the adoption of national treatment guidelines, particularly among primary care physicians (PCPs). Perceived issues with payer coverage (due to prior authorization complexity/rejections) and high out-of-pocket costs/inability to afford treatment were found to be the leading factors negatively impacting treatment initiation or causing treatment disruptions.
"Salix is committed to delivering resources that inform, educate and help health care providers improve the care of people living with chronic liver disease, cirrhosis, and complications such as hepatic encephalopathy," said Nicola Kayel , vice president, GI Marketing, Salix. "This year's report points to a continued rise in mortality from chronic liver disease and cirrhosis, now outpacing diabetes or stroke among those 25-54 years old 1 . It's clear from both patient and provider research that there's a real need for more education and engagement resources to support the management of CLD. It is our hope the Salix Liver Health Annual Trends Report will increase awareness of this growing public health concern, help bridge the knowledge gap, and provide tools for health care providers that may improve identification and management of the disease."
The Salix Liver Health Annual Trends Report is being released in October during Liver Health Awareness Month as part of an effort to equip health care providers with the most current information on liver disease.
"The Global Liver Institute applauds the publication of this year's Liver Health Annual Trends Report which will help bring better understanding of the personal and societal impact of chronic liver disease and potentially help address its under-diagnosis and under-treatment among the approximately 4.5 million adults in the U.S. living with the disease 2 ," said Donna R. Cryer , JD, founder and CEO, Global Liver Institute.
Complete findings from Salix's Liver Health Annual Trends Report as well as health care provider resources to help identify and manage patients with CLD and cirrhosis can be viewed at LiverHEalthNow.com .
Select findings from the report include:
About the Methodology Behind Liver Health Annual Trends Report
The Liver Health Annual Trends Report on chronic liver disease (CLD) includes information collected from an online survey, qualitative telephone interviews, and secondary research from peer-reviewed publications. An independent third-party recruiting firm invited over 400 health care providers to participate in this research project during May 2022 . Provider participation (N=400) in the survey required individuals to be active in clinical practice and treat more than 4 CLD patients annually and were comprised of the following subgroups: 100 community-based gastroenterologists, 100 institution-based specialists, 100 primary care physicians (PCPs), and 100 nurse practitioners/physician assistants (NPs/PAs). In addition to completing the online survey, 15 physicians and 5 NPs/PAs also completed in-depth telephone interviews (Table 1). Quotes from the in-depth interviews throughout this report represent the opinions of those responders. As it pertains to the online survey, analysis of the data was conducted by utilizing QPSMR data analysis software.
The report strives to be representative of all physician segments' lived experience and the diversity that exists within the United States with respect to patient management and the economic and social factors that impact the management of CLD patients. Due to the limitations of this report, not all findings may be generalizable to the larger CLD provider and patient populations. In addition, this report does not contain all questions asked in the survey and in-depth interviews.
Secondary Research of Peer-Reviewed Publications
Secondary research was conducted utilizing Google and PubMed searches to identify relevant peer-reviewed publications and sources as noted in the report. Furthermore, treatment utilization and claims data were sourced from IQVIA. Secondary research may not reflect all published data. A systematic review was not performed. While included publications are peer reviewed, this secondary research as a whole was not.
To raise awareness and knowledge of CLD and HE, Salix also offers other online resources including:
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey . For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn .
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch + Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health.
This news release may contain forward-looking statements about the future performance of the Company, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to the Company's overall business, including those more fully described in the Company's most recent annual report on Form 10-K and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian securities administrators, which factors are incorporated herein by reference.
©2022 Salix Pharmaceuticals or its affiliates.
1 Xu JQ, Murphy SL, Kochanek KD, Arias E. Deaths: final data for 2019. Natl Vital Stat Rep. 70(8). Hyattsville, MD : National Center for Health Statistics. 2021.
2 Centers for Disease Control and Prevention. Chronic liver disease and cirrhosis. Accessed September 9, 2022 . https://www.cdc.gov/nchs/fastats/liver-disease.htm
View original content to download multimedia: https://www.prnewswire.com/news-releases/salix-pharmaceuticals-releases-liver-health-annual-trends-report-underscoring-challenges-in-caring-for-growing-chronic-liver-disease-and-cirrhotic-patient-population-301646728.html
SOURCE Bausch Health Companies Inc.
News Provided by PR Newswire via QuoteMedia
As we enter cold and flu season amid continuing COVID-19 cases, Abbott (NYSE: ABT), makers of BinaxNOW™ COVID-19 Antigen Self Test and The Home Edit, the world's number one organizational company and a global lifestyle brand, are partnering to redesign the medicine cabinet for today's health needs. Together, Abbott and The Home Edit will provide organization tips and advice on healthcare essentials to have on hand to feel more prepared and in control this season.
As COVID-19 becomes endemic, many aspects of family life have changed—including the types of products and medicines that families have on hand. People are growing more accustomed to managing their health from home, from vitamins and digital thermometers to Pedialyte ® with Immune Support for hydration. At-home COVID-19 tests have become a necessity, as they give results in minutes, providing peace of mind and the ability to take action to quickly slow the spread of the virus.
"We love helping families get organized and there's no better time of year to do it than now," said Clea Shearer and Joanna Teplin , founders of The Home Edit. "Going through your medicine cabinet and making sure you have health and wellness products on hand and organized can help you feel prepared for whatever the season brings. Essentials like BinaxNOW have become a staple in our medicine cabinets to keep our families protected from COVID-19."
To help families get ready for cold and flu season, Clea and Joanna are sharing how best to organize a medicine cabinet for preparedness and convenience, including their must-haves for keeping a cabinet well stocked, and in their signature style, also making it visually appealing.
The big impact of small acts of organization
Home organization is not only good for being prepared, but also can have surprising mental benefits as well.
"Many have faced mental health challenges during the pandemic including a sense of powerlessness due to all the unknowns," said Andrea Bonior , Ph.D., clinical psychologist and professor at Georgetown University . "Research has shown that organization can reduce stress and bring back some sense of control in these types of situations. Knowing that you have the ability to have answers and medicines on hand when sicknesses show up will add an extra layer of peace of mind."
Abbott has produced more than a billion BinaxNOW tests to help communities, organizations and families have access to reliable and quick results. The company's U.S. manufacturing facilities continue to make tens of millions of tests per month.
"While we still have a lot to learn about COVID-19, one thing that we know for sure is that it's not going away," says Aparna Ahuja , M.D., head of clinical and medical affairs, infectious diseases, Abbott. "Having rapid tests on hand will be critical to staying safe this season by ensuring that COVID-19 infections are diagnosed quickly, so the appropriate measures can be taken to get well and avoid the risk of spreading an infection."
Learn more about Abbott's BinaxNOW Self Test and tips on organizing your health space here .
About BinaxNOW COVID-19 Tests
As the #1 COVID-19 self test in the U.S., the BinaxNOW at-home test is readily available over-the-counter at retailers across the country and provides results in 15 minutes. BinaxNOW is both FSA and HSA eligible, and insurance plans may cover up to eight over-the-counter, at-home COVID-19 tests per covered individual per month.
The rapid antigen test is authorized for home use using a simple nasal swab by people with or without symptoms aged 15 years or old, or on individuals two years or older when collected by an adult. Each kit box contains two test cards to enable test twice over 3 days, with at least 24 (and no more than 48) hours apart.
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .
About The Home Edit
The Home Edit was founded in 2015 by Clea Shearer and Joanna Teplin with the goal of reinventing traditional organizing and merging it with design. Since then, it has grown into a global media and organization company with a social following of over 7 million people and organizing teams in cities across the country. The Home Edit has become a household name thanks to two New York Times' bestselling books, an Emmy-nominated Netflix show, "Get Organized with the Home Edit," and a successful line of organizational products sold in stores in over 27 countries, including at its most recent retail partner, Walmart. In 2022, The Home Edit was acquired by Hello Sunshine/Candle Media.
The BinaxNOW™ COVID-19 Antigen Self Test is a lateral flow immunoassay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 infection when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests. This test is authorized for non-prescription home use with self-collected direct anterior nasal (nares) swab samples from individuals aged 15 years or older or adult collected anterior nasal (nares) swab samples from individuals aged two years or older.
The BinaxNOW™ COVID-19 tests have not been FDA cleared or approved. They have been authorized by the FDA under an emergency use authorization. They have been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. For serial testing, the BinaxNOW COVID-19 Antigen Tests should be performed twice over 3 days, at least 24 hours (and no more than 48 hours) apart. For symptomatic use, a single test can be used.
View original content to download multimedia: https://www.prnewswire.com/news-releases/abbott-and-the-home-edit-redesign-the-medicine-cabinet-to-help-people-prepare-for-the-upcoming-virus-season-301647415.html
News Provided by PR Newswire via QuoteMedia
"Engineering impact" highlights the Company's progress toward health equity, workforce diversity and net zero emissions
Medtronic plc today released its fiscal year (FY) 2022 Integrated Performance Report: Engineering impact. The report highlights the Company's progress on its ESG strategy, including measurable impact across patient access and equity; life-transforming healthcare technology; inclusion, diversity and equity (ID&E) and environmental sustainability.
"The Medtronic Mission — to alleviate pain, restore health and extend life — unites our diverse team of more than 95,000 people whose work transforms the lives of two people every second. And despite the global challenges faced over the past year, we maintained our steadfast commitment to carrying out the Mission and increasing our environmental, social and governance efforts.
-Geoff Martha, Chairman and CEO, Medtronic
Key ESG accomplishments in FY22
Patient access and equity : Medtronic remained focused on advancing healthcare equity and expanding access to its lifesaving products and therapies. In FY22, the Company:
Life-transforming healthcare technology: Medtronic furthered its position as a healthcare technology leader, leveraging patient-first innovations that personalize healthcare and promote positive outcomes. In FY22, the Company:
Inclusion, diversity and equity : Groundbreaking innovation comes from an inclusive, diverse and equitable workforce. In FY22, the Company:
Environmental sustainability: The Company made strong progress toward its FY45 ambition to achieve net zero emissions. In FY22, the Company:
The 2022 Integrated Performance Report, as well as other ESG updates, are available on the Medtronic website .
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems and more. Powered by our diverse knowledge, insatiable curiosity and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn.
1 This includes our C-suite and their direct reports, including 160 leaders at the vice president level and above.
View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-releases-2022-integrated-performance-report-301645186.html
SOURCE Medtronic plc
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2022/11/c2008.html
News Provided by Canada Newswire via QuoteMedia
Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for tafasitamab in combination with lenalidomide to ANVISA, the Brazilian health regulatory agency, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
In September 2021, Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi ® in the United States and Minjuvi ® in Europe), as well as pemigatinib (Pemazyre ® ), in Latin America.
"We are delighted to reach this key milestone for tafasitamab in Brazil," said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics. "Upon approval, combination therapy with tafasitamab and lenalidomide will be an important new therapeutic option for eligible patients with relapsed or refractory DLBCL in Brazil. We look forward to continuing to work with the support of our partner, Incyte, as we work towards regulatory submissions in additional countries in Latin America over the next year."
Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb ® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).
In the United States, Monjuvi ® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplantation (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
In Europe, Minjuvi ® (tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.
Minjuvi ® and Monjuvi ® are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi ® in the U.S., and marketed by Incyte under the brand name Minjuvi ® in Region Europe, the United Kingdom and Canada. As part of its agreement with MorphoSys, Incyte received exclusive commercialization rights for tafasitamab outside the United States.
XmAb ® is a registered trademark of Xencor, Inc.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or www.sedar.com .
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2021 as filed on www.sedar.com . Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law.
A new study published in The New England Journal of Medicine finds that for adults with Type 1 diabetes and sub-optimal glycemic control, Abbott's FreeStyle Libre ® 2 glucose monitoring system provided significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose (SMBG), which were sustained for the study duration of 24 weeks.1 Use of the FreeStyle Libre 2 system was also linked to improvements in participant-reported quality of life outcomes, including overall satisfaction and reduction in burden associated with glucose monitoring.
After six months, people who used the FreeStyle Libre 2 system reduced their HbA1c levels by an average of 0.8% (8.7% to 7.9%). 1 Lowering HbA1c by this amount can decrease the risk of developing diabetes complication in the future. In comparison, people using SMBG reduced their HbA1c levels by an average of only 0.2% (8.5% to 8.3%). 1
HbA1c provides an estimate of average glucose levels over the preceding three months and is the standard measurement of glycemic control for people with diabetes. 2 Increased HbA1c is associated with a greater risk of developing complications related to diabetes, such as cardiovascular disease, kidney disease and eye problems. 3
"Continuous glucose monitoring has been a critical tool for people living with diabetes, both to avoid painful fingersticks and to help manage glucose levels," said study author Dr. Lalantha Leelarathna from the University of Manchester NHS Foundation Trust. "This data adds to the growing body of evidence that demonstrates the technology helps bring HbA1c levels closer to the target range, which ultimately decreases risks of further complications."
The trial included 156 people aged 16 years or older with Type 1 diabetes and HbA1c levels of 7.5% to 11%, none of whom had previously used continuous glucose sensing technology. For 24 weeks, half the participants were randomized to monitor their glucose with the FreeStyle Libre 2 system and the other half with SMBG.
The average HbA1c level of participants using the FreeStyle Libre 2 system was 0.3% lower at 12 weeks and 0.5% lower at 24 weeks, statistically significant compared to those using SMBG. FreeStyle Libre users also had a greater likelihood of reducing their HbA1c by a full percentage point by the end of the study period. They spent an additional 130 minutes per day with glucose levels in the target range (70-180 mg/dL) and 43 minutes per day less time with dangerously low glucose levels (
FreeStyle Libre 2 users also reported a positive impact on quality of life, captured by participant-reported answers to the Diabetes Treatment Satisfaction Questionnaire and the Glucose Monitoring Satisfaction Survey. At 24 weeks, these participants reported greater overall treatment satisfaction and reduced burden associated with glucose monitoring.
"This randomized study clearly illustrates the importance of continuous glucose monitoring for adults with Type 1 diabetes," said Dr. Mahmood Kazemi , chief medical officer for Abbott's diabetes care business. "This clinically-significant change in HbA1c levels shows FreeStyle Libre technology empowers people to make lifestyle decisions that improve their glucose control and, ultimately, may result in a reduction in diabetes-related health problems down the line."
The study is part of FLASH-UK, the first randomized clinical trial of the FreeStyle Libre 2 system compared to SMBG. It was led by a team at The University of Manchester together with investigators from eight centers in the United Kingdom ( Birmingham , Cambridge , Derby , Dorset , Ipswich , Manchester , Norwich and Portsmouth ) and funded by Diabetes UK. Abbott was not involved in the execution or funding of the study.
Abbott's FreeStyle Libre systems include a sensor, which is applied to the back of the upper arm for up to 14 days and continuously measures glucose, paired with a compatible smartphone app 4 or reader that display glucose readings. The FreeStyle Libre portfolio is the number one sensor-based glucose monitoring system in the world 5 , having changed the lives of more than 4 million people across more than 60 countries 6 by providing breakthrough technology that is accessible and affordable. 7
Abbott (NYSE: ABT) is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews .
FreeStyle Libre 2 system : Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.
1 Leelarathna L, Evans M, Neupane S, et al. (2022) Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes. New England Journal of Medicine, Oct. 5 , DOI: 10.1056/NEJMoa2205650
2 World Health Organization. Use of Glycated Hemoglobin (HbA1C) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation Published. 2011. p. 2, Glycated hemoglobin (HbA1c) for the diagnosis of diabetes. Available online at: https://www.who.int/diabetes/publications/report-hba1c_2011.pdf . Last accessed April 2022 .
3 Sherwani SI, Khan HA, Ekhzaimy, et al. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomarker Insights 2016:11 95–104 doi: 10.4137/BMI.S38440
4 The app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app.
5 Data on file, Abbott Diabetes Care. Data based on the number of users worldwide for the FreeStyle Libre portfolio compared to the number of users for other leading personal use, sensor-based glucose monitoring systems.
6 Data on file. Abbott Diabetes Care.
7 Based on a comparison of list prices of the FreeStyle Libre portfolio versus competitor CGM systems available worldwide. The actual cost to patients may or may not be lower than other CGM systems, depending on local reimbursement, if any.
View original content to download multimedia: https://www.prnewswire.com/news-releases/new-study-published-in-the-new-england-journal-of-medicine-demonstrates-abbotts-freestyle-libre-2-system-has-positive-impacts-on-glucose-levels-and-quality-of-life-301642360.html
News Provided by PR Newswire via QuoteMedia
– Danaher Corporation (NYSE: DHR) (the "Company"), the global science and technology innovator, today published its 2022 Sustainability Report which highlights the progress of the Company's sustainability program. Danaher also announced it has set a new goal to reduce its absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 50.4% by 2032, compared to a baseline year of 2021—aligning to the prevailing climate science goal of limiting global warming to 1.5 degrees Celsius above pre-industrial levels.
"Every day across Danaher, we work to positively impact the world around us in meaningful ways," said Rainer Blair , President and Chief Executive Officer. "We feel a strong sense of responsibility to exceed the expectations of our stakeholders across the many facets of sustainability, and within this challenge we see tremendous opportunity to help all our stakeholders Realize Life's Potential . Thanks to the driving force of the Danaher Business System, we have made notable progress across our sustainability endeavors this year and are excited to set our future ambitions even higher."
This year's report conveys the depth and scope of Danaher's commitment to sustainability and details several important milestones the Company achieved across its three sustainability strategic pillars during the past year:
Innovating Products That Improve Lives and Our Planet
Investing in our innovation ecosystem
Building the Best Team
Expanded commitment to diversity and inclusion (D+I)
Protecting Our Environment
Established ambitious new GHG emission reduction target
"As global stewards of the environment, we recognize an increasingly urgent need to take swift action to address climate change. The progress we achieved against our original GHG emissions target gives us confidence as we embrace a bold new goal, and we expect that our powerful suite of DBS tools and processes will be a key driver of future reductions," Mr. Blair concluded. "We know that when we bring together the scope and scale of our innovations, the passion and dedication of our team, and our deeply ingrained commitment to continuous improvement, the potential for long-term positive impact is limitless."
Danaher is committed to helping generations of our stakeholders Realize Life's Potential by innovating products that improve lives and our planet, building the best team, and protecting our environment. Our dedication to continuous improvement drives us to positively impact the world around us every day and the Danaher Business System is a uniquely powerful system for supporting these ambitions. To learn more about Danaher's sustainability initiatives and to read or download the 2022 sustainability report, please visit www.danaher.com/sustainability
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 80,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential . For more information, please visit www.danaher.com
Statements in this release that are not strictly historical, including any statements regarding events or developments that we anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, those set forth in our SEC filings, including our 2021 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the second quarter of 2022. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
View original content: https://www.prnewswire.com/news-releases/danaher-releases-2022-sustainability-report-and-announces-new-greenhouse-gas-emissions-reduction-target-301641899.html
SOURCE Danaher Corporation
News Provided by PR Newswire via QuoteMedia
CMS Issues New Clarification on ICD-10 Coding for SAD
Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") is continuing its commitment to improving lives with the announcement of modifications within the Tabular Index, specifically for the prevention and treatment of SAD from the Centers for Medicare & Medicaid Services (CMS). Now, all appropriate codes have been combined into a bundle for SAD which allows healthcare professionals to further clarify a diagnosis in an easy-to-understand index tab and send all diagnoses for SAD to one simple code: F33. This achievement helps further define SAD as a recognizable condition that may be diagnosed and appropriately treated.
More than 16 million people suffer from SAD in the United States alone. 1,2 While the symptoms of SAD can be the same as those of Major Depressive Disorder (MDD), many people with SAD may experience these symptoms more frequently during the fall or winter months and may benefit from a treatment that does not need to be taken year-round. 3-6
Prior to this important modification of the Tabular Index, it is believed that SAD has been underdiagnosed 7 and the ICD-10 is used to properly classify a disease and diagnosis. As of Oct. 1, 2022 , healthcare professionals will have access to a new instructional note for SAD at F33 in the Tabular Index and with that, sufferers may be more appropriately identified and prescribed an FDA-approved treatment for SAD.
To learn more about the Federal Register announcement, please visit here: https://www.cdc.gov/nchs/icd/comprehensive-listing-of-icd-10-cm-files.htm
APLENZIN (bupropion hydrobromide) is an antidepressant indicated for the treatment of MDD and prevention of SAD. APLENZIN is the only FDA-approved bupropion hydrobromide indicated for the prevention of SAD and offers more than 20 years of combined clinical experience in MDD and SAD. 6,8-10 APLENZIN is a once-daily, single tablet available in 3 dosage strengths, with no generic substitute. 6,10 Recommended dosing for patients with SAD includes initiating treatment in the fall and discontinuing in early spring, as prescribed by a healthcare professional. For more information, visit www.aplenzin.com .
About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our healthcare products. We develop, manufacture, and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health through our approximately 88.7% ownership of Bausch + Lomb Corporation. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .
This news release may contain forward-looking statements about Bausch Health, which may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to," and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
APLENZIN® (bupropion hydrobromide extended-release tablets) is a prescription medicine used to treat adults with a certain type of depression called major depressive disorder, and for the prevention of autumn-winter seasonal depression (seasonal affective disorder).
IMPORTANT SAFETY INFORMATION
WARNING: CHANGES IN THINKING AND BEHAVIOR, DEPRESSION, AND SUICIDAL THOUGHTS OR ACTIONS
Suicidal Thoughts or Actions and Antidepressant Drugs
Antidepressants may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. People who have (or have a family history of) bipolar illness or suicidal thoughts or actions may have a particularly high risk. Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if symptoms such as anxiety, irritability, impulsivity, trouble sleeping, aggressive behavior or suicidal thoughts are new, worse or worry you. APLENZIN has not been evaluated for use in patients under the age of 18.
Call your healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:
Although APLENZIN is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking.
Some people have had serious side effects while taking bupropion to help them quit smoking, including:
New or worse mental health problems, such as changes in behavior or thinking, aggression, hostility, agitation, depression, or suicidal thoughts or actions. Some people had these symptoms when they began taking bupropion, and others developed them after several weeks of treatment, or after stopping bupropion. These symptoms happened more often in people who had a history of mental health problems before taking bupropion than in people without a history of mental health problems.
Stop taking APLENZIN and call your healthcare provider right away if you, your family, or caregiver notice any of these symptoms. Work with your healthcare provider to decide whether you should continue to take APLENZIN. In many people, these symptoms went away after stopping APLENZIN, but in some people, symptoms continued after stopping APLENZIN. It is important for you to follow-up with your healthcare provider until your symptoms go away.
Before taking APLENZIN, tell your healthcare provider if you have ever had depression or other mental health problems. You should also tell your healthcare provider about any symptoms you had during other times you tried to quit smoking, with or without bupropion.
What Other Important Information Should I Know About APLENZIN?
Do not take APLENZIN if you:
Although APLENZIN is not a treatment for quitting smoking, it contains the same active ingredient (bupropion) as ZYBAN, which is used to help patients quit smoking. Before taking APLENZIN, tell your healthcare provider if you have ever had depression, suicidal thoughts or actions, or other mental health problems or any symptoms you had during other times you tried to quit smoking with or without bupropion. Also, tell your healthcare provider about your other medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Many medicines increase your chances of having seizures or cause other serious side effects if you take them while you are using APLENZIN.
The most common side effects of APLENZIN include: trouble sleeping, stuffy nose, dry mouth, dizziness, feeling anxious, nausea, constipation, and joint aches.
Click here to read the Medication Guide carefully before you start using APLENZIN. If you have any questions about APLENZIN, ask your healthcare provider or pharmacist.
Click here for full Prescribing Information, including Medication Guide and Boxed Warning regarding suicidal thoughts and actions.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also contact Bausch Health Customer Service at 1-800-321-4576.
APLENZIN is a trademark of Bausch Health Companies Inc. or its affiliates.
Any other product/brand names and/or logos are trademarks of the respective owners.
© 2022 Bausch Health Companies Inc. or its affiliates.
(877) 281-6642 (toll free)
View original content to download multimedia: https://www.prnewswire.com/news-releases/seasonal-affective-disorder-sad-is-now-a-recognized-diagnosis-in-the-cms-tabular-index-accessible-to-prescribers-oct-1-2022-301641004.html
SOURCE Bausch Health Companies Inc.
News Provided by PR Newswire via QuoteMedia